OpenURL Connection Search

Select item for more details and to access through your institution.

Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?
Published in:
2010
By:
- Solal-Céligny, Ph.;
- Cahu, X.;
- Cartron, G.;
- Solal-Céligny, Ph
Publication type:
journal article
Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand.
Published in:
2003
By:
- Cartron, G;
- Binet, C;
- Hérault, O;
- Cailliot, C;
- Bernard, M C;
- Estienne, M H;
- Clément, N;
- Colombat, Ph;
- Domenech, J
Publication type:
journal article
Persistent decrease in proliferative potential of marrow CD34[sup+] cells exposed to early-acting growth factors after autologous bone marrow transplantation.
Published in:
Bone Marrow Transplantation, 2002, v. 29, n. 7, p. 557, doi. 10.1038/sj.bmt.1703512
By:
- Domenech, J.;
- Cartron, G.;
- Clement, N.;
- Estienne, M.-H.;
- Herault, O.;
- Truglio, D.;
- Benboubker, L.;
- Roingeard, F.;
- Desbois, I.;
- Colombat, P.;
- Benet, C.
Publication type:
Article
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
Published in:
Annals of Hematology, 2022, v. 101, n. 5, p. 1015, doi. 10.1007/s00277-022-04779-x
By:
- Robin, J. B.;
- Theron, A.;
- Quittet, P.;
- Exbrayat, C.;
- Gaillard, J. B.;
- Lavabre-Bertrand, T.;
- David, S.;
- Saad, A.;
- Jourdan, E.;
- Cartron, G.
Publication type:
Article
Bénéfices des activités physiques adaptées au cours de l'allogreffe de cellules souches hématopoïétiques : étude de faisabilité.
Published in:
Oncologie (Tech Science Press), 2015, v. 17, n. 1/2, p. 47, doi. 10.1007/s10269-015-2486-3
By:
- Lemercier, L.;
- Bernard, P.;
- Delmotte, J.;
- Vincent, L.;
- Cartron, G.;
- Ninot, G.
Publication type:
Article
JS1.4 Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: A French neurological multi-center survey.
Published in:
Neuro-Oncology, 2019, v. 21, p. iii5, doi. 10.1093/neuonc/noz126.013
By:
- Belin, C;
- Simard, C;
- Santos, A Dos;
- Ayrignac, X;
- Berger, C;
- Cartron, G;
- Gouill, S Le;
- Sesques, P;
- Thieblemont, C;
- Carpentier, A F
Publication type:
Article
Sezary syndrome in a patient with multiple myeloma: demonstration of a clonally distinct second malignancy.
Published in:
European Journal of Haematology, 1999, v. 63, n. 5, p. 354, doi. 10.1111/j.1600-0609.1999.tb01139.x
By:
- Cartron, G.;
- Roingeard, Ph.;
- Benboubker, L.;
- Vaillant, L.;
- Tartas, S.;
- Delain, M.;
- Lefranc, T.;
- Brémond, J. L.;
- Bout, M.;
- Linassier, C.;
- Colombat, Ph.
Publication type:
Article
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2023, v. 41, p. 877, doi. 10.1002/hon.3196_LBA4
By:
- Morschhauser, F.;
- Dahiya, S.;
- Palomba, M. L.;
- Garcia‐Sancho, A. M.;
- Ortega, J. L. Reguera;
- Kuruvilla, J.;
- Jager, U.;
- Cartron, G.;
- Izutsu, K.;
- Dreyling, M.;
- Kahl, B.;
- Ghesquieres, H.;
- Ardeshna, K.;
- Goto, H.;
- Barbui, A. M.;
- Abramson, J. S.;
- Borchmann, P.;
- Fleury, I.;
- Mielke, S.;
- Farazi, T.
Publication type:
Article
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 147, doi. 10.1002/hon.3163_97
By:
- Houot, R.;
- Bachy, E.;
- Cartron, G.;
- Gros, F.;
- Morschhauser, F.;
- Oberic, L.;
- Gastinne, T.;
- Feugier, P.;
- Dulery, R.;
- Thieblemont, C.;
- Joris, M.;
- Jardin, F.;
- Choquet, S.;
- Casasnovas, O.;
- Brisou, G.;
- Cheminant, M.;
- Bay, J.;
- Gutierrez, F. Llamas;
- Menard, C.;
- Tarte, K.
Publication type:
Article
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2023, v. 41, p. 825, doi. 10.1002/hon.3166_OT08
By:
- Bachy, E.;
- Ramakrishnan, A.;
- Thieblemont, C.;
- Alfonso, A.;
- Braunschweig, I.;
- Riedell, P. A.;
- Cartron, G.;
- Barba, P.;
- Gastinne, T.;
- Simon, J. A. Perez;
- Solano, C.;
- Meadows, S.;
- LaCroce, A.;
- Thomas, D.;
- Poirot, C.;
- Newhall, K. J.;
- Lee, D. J.;
- Frattini, M. G.;
- Abramson, J.
Publication type:
Article
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 144, doi. 10.1002/hon.3163_95
By:
- Dickinson, M.;
- Carlo‐Stella, C.;
- Morschhauser, F.;
- Falchi, L.;
- Bachy, E.;
- Cartron, G.;
- Khan, C.;
- Tani, M.;
- Martinez‐Lopez, J.;
- Bartlett, N.;
- Salar, A.;
- Brody, J.;
- Leppä, S.;
- Mulvihill, E.;
- Lundberg, L.;
- Relf, J.;
- Xie, Y.;
- Bottos, A.;
- Humphrey, K.;
- Hutchings, M.
Publication type:
Article
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 136, doi. 10.1002/hon.3163_91
By:
- Hutchings, M.;
- Dickinson, M.;
- Carlo‐Stella, C.;
- Morschhauser, F.;
- Bosch, F.;
- Gritti, G.;
- Townsend, W.;
- Bartlett, N. L.;
- Cartron, G.;
- Ghesquieres, H.;
- Houot, R.;
- Walter, H.;
- Offner, F.;
- Christiansen, A.;
- Dimier, N.;
- Jamois, C.;
- Harrop, E.;
- Herter, S.;
- Hölzlwimmer, G.;
- Keelara, A.
Publication type:
Article
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 108, doi. 10.1002/hon.3163_69
By:
- Loyaux, R.;
- Sako, N.;
- Quang, V. Tran;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Gressin, R.;
- Daguindau, N.;
- Le Gouill, S.;
- Wolfromm, A.;
- Bouabdallah, K.;
- Ysebaert, L.;
- Casasnovas, O.;
- Robe, C.;
- Delfau, M.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Sloma, I.;
- Lemonnier, F.
Publication type:
Article
'Don't keep me waiting': estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ setting.
Published in:
Hematological Oncology, 2023, v. 41, p. 541, doi. 10.1002/hon.3164_401
By:
- Maziarz, R.;
- Vadgama, S.;
- Pasquini, M.;
- Hu, Z.;
- Ray, M.;
- Smith, H.;
- Bullement, A.;
- Edmondson‐Jones, M.;
- Sullivan, W.;
- Cartron, G.
Publication type:
Article
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.
Published in:
Hematological Oncology, 2023, v. 41, p. 534, doi. 10.1002/hon.3164_397
By:
- Vic, S.;
- Thibert, J.;
- Bachy, E.;
- Cartron, G.;
- Gastinne, T.;
- Morschhauser, F.;
- Le Bras, F.;
- Bouabdallah, K.;
- Despas, F.;
- Bay, J.;
- Rubio, M.;
- Mohty, M.;
- Casasnovas, O.;
- Choquet, S.;
- Castilla‐Llorente, C.;
- Guidez, S.;
- Loschi, M.;
- Guffroy, B.;
- Carras, S.;
- La Rochelle, L. Drieu
Publication type:
Article
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study.
Published in:
Hematological Oncology, 2023, v. 41, p. 512, doi. 10.1002/hon.3164_378
By:
- Tournilhac, O.;
- Altmann, B.;
- Friedrichs, B.;
- Bouabdallah, K.;
- Cartron, G.;
- Nickelsen, M.;
- Wulf, G.;
- Leclerc, M.;
- Vilatte, A.;
- Turlure, P.;
- Sanhès, L.;
- Houot, R.;
- Roussel, M.;
- de Leval, L.;
- Rosenwald, A.;
- Gaulard, P.;
- Dreger, P.;
- Glass, B.;
- Latière, C.;
- Damaj, G.
Publication type:
Article
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination.
Published in:
Hematological Oncology, 2023, v. 41, p. 478, doi. 10.1002/hon.3164_352
By:
- Le Gouill, S.;
- Morschhauser, F.;
- Chiron, D.;
- Bouabdallah, K.;
- Cartron, G.;
- Casasnovas, O.;
- Rule, S.;
- Bodet‐Milin, C.;
- Herbaux, C.;
- Gastinne, T.;
- Callanan, M.;
- Tessoulin, B.
Publication type:
Article
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study.
Published in:
Hematological Oncology, 2023, v. 41, p. 338, doi. 10.1002/hon.3164_241
By:
- Sako, N.;
- Delfau, M.;
- Bachy, E.;
- Morschhauser, F.;
- Cartron, G.;
- Casasnovas, O.;
- Gressin, R.;
- Daguindau, N.;
- Tournilhac, O.;
- Bouabdallah, K.;
- Le Gouill, S.;
- Andre, M.;
- Robe, C.;
- Dupuis, J.;
- De Leval, L.;
- Gaulard, P.;
- Lemonnier, F.
Publication type:
Article
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial.
Published in:
Hematological Oncology, 2023, v. 41, p. 290, doi. 10.1002/hon.3164_200
By:
- Mozas, P.;
- Ammar, R. Ould;
- Chartier, L.;
- Nastoupil, L.;
- Bachy, E.;
- Bezsera, S. M.;
- Barnes, J.;
- Bijou, F.;
- Goy, A.;
- Zerazhi, H.;
- Cartron, G.;
- Ojeda‐Uribe, M.;
- Choquet, S.;
- Joly, B.;
- Cheminant, M.;
- García‐Sancho, A. Martín;
- Eradat, H.;
- Gressin, R.;
- Abrisqueta, P.;
- Parcelier, A.
Publication type:
Article
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
Published in:
Hematological Oncology, 2023, v. 41, p. 239, doi. 10.1002/hon.3163_156
By:
- Kater, A. P.;
- Harrup, R.;
- Kipps, T. J.;
- Eichhorst, B.;
- Owen, C. J.;
- Assouline, S.;
- Lamanna, N.;
- Robak, T.;
- Serna, J. d. l.;
- Jaeger, U.;
- Cartron, G.;
- Montillo, M.;
- Mellink, C.;
- Chyla, B.;
- Thadani‐Mulero, M.;
- Lefebure, M.;
- Jiang, Y.;
- Millen, R.;
- Boyer, M.;
- Seymour, J. F.
Publication type:
Article
PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSA.
Published in:
Hematological Oncology, 2023, v. 41, p. 202, doi. 10.1002/hon.3163_132
By:
- Sesques, P.;
- Di blasi, R.;
- Legouill, S.;
- Cartron, G.;
- Beauvais, D.;
- Le Bras, F.;
- Gros, F.;
- Choquet, S.;
- Bories, P.;
- Rubio, M.;
- Casasnovas, R.;
- Bay, J.;
- Mohty, M.;
- Joris, M.;
- Abraham, J.;
- Llorente, C. Castilla;
- Loschi, M.;
- Carras, S.;
- Chauchet, A.;
- Gyan, E.
Publication type:
Article
EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 179, doi. 10.1002/hon.3163_113
By:
- Delfau‐Larue, M.;
- Viailly, P.;
- Cartron, G.;
- Morschhauser, F.;
- Gros, F.;
- Gastinne, T.;
- Oberic, L.;
- Bachy, E.;
- Dulery, R.;
- Feugier, P.;
- Menard, C.;
- Quelen, C.;
- Pangault, C.;
- Portugues, C.;
- Gomes, L.;
- Itti, E.;
- Bailly, C.;
- Lemonnier, F.;
- Laurent, C.;
- Houot, R.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY (EUDRACT NUMBER: 2015‐005612‐15)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.87_2880
By:
- Maerevoet, M.;
- Casasnovas, O.;
- Cartron, G.;
- Morschhauser, F.;
- Thieblemont, C.;
- Bouabdallah, K.;
- Feugier, P.;
- Szablewski, V.;
- Becker, S.;
- Tilly, H.
Publication type:
Article
FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.84_2879
By:
- Le Gouill, S.;
- Bachy, E.;
- Di Blasi, R.;
- Cartron, G.;
- Beauvais, D.;
- Le Bras, F.;
- Gros, François‐X.;
- Choquet, S.;
- Bories, P.;
- Rubio, Marie‐Thérès.;
- Casasnovas, René‐O.;
- Bounaix, L.;
- Mohty, M.;
- Joris, M.;
- Gastinne, T.;
- Sesques, P.;
- Tudesq, J. J.;
- Morschhauser, F.;
- Gat, E.;
- Broussais, F.
Publication type:
Article
IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASIS.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.79_2881
By:
- Devin, J.;
- Cañeque, T.;
- Lin, Y.‐L.;
- Mondoulet, L.;
- Veyrune, J.‐L.;
- Abouladzé, M.;
- Garcia de Paco, E.;
- Gadacha, O.;
- Cartron, G.;
- Pasero, P.;
- Bret, C.;
- Rodriguez, R.;
- Moreaux, J.
Publication type:
Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.57_2880
By:
- Herbaux, C.;
- Schiano de Colella, J. M.;
- Thieblemont, C.;
- Guidez, S.;
- Ysebaert, L.;
- Tilly, H.;
- Le Gouill, S.;
- Houot, R.;
- Bachy, E.;
- Laurent, C.;
- Damaj, G.;
- Feugier, P.;
- Morineau, N.;
- Tarte, K.;
- Morschhauser, F.;
- Cartron, G.
Publication type:
Article
CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.3_2880
By:
- Bohers, E;
- Delfau‐Larue, M;
- Vercellino, L;
- Cottereau, A;
- Viennot, M;
- Viailly, P;
- Salles, G;
- Tilly, H;
- Damaj, G;
- Haioun, C;
- Ribrag, V;
- Morschhauser, F;
- Casasnovas, R;
- Nicolas‐Virelizier, E;
- Feugier, P;
- Bouabdallah, R;
- Cartron, G;
- Renaud, L;
- Chartier, L;
- Portugues, C
Publication type:
Article
ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.22_2880
By:
- Cartron, G.;
- Bachy, E.;
- Guidez, S.;
- Gyan, E.;
- Gressin, R.;
- Morineau, N.;
- Sibon, D.;
- Casasnovas, O.;
- Le Gouill, S.;
- Tilly, H.;
- Ysebaert, L.;
- Schiano de Colella, J. M.;
- Feugier, P.;
- Virelizier, E. Nicolas;
- Haioun, C.;
- Damaj, G.;
- Tarte, K.;
- Laurent, C.;
- Houot, R.;
- Thieblemont, C.
Publication type:
Article
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.173_2880
By:
- Morschhauser, F.;
- Nowakowski, G. S.;
- Cartron, G.;
- Kesanakurthy, V.;
- Gkasiamis, A.;
- Patah, P.;
- Delarue, R.;
- Wang, T.;
- Li, J.;
- Xian, D.;
- Fox, C. P.;
- Martin, P.
Publication type:
Article
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.157_2880
By:
- Al Tabaa, Y.;
- Casasnovas, O.;
- Baillet, C.;
- Bachy, E.;
- Virelizier, E. Nicolas;
- Schiano de Colella, J. M.;
- Bailly, C.;
- Kanoun, S.;
- Guidez, S.;
- Gyan, E.;
- Gressin, R.;
- Morineau, N.;
- Ysebaert, L.;
- Le Gouill, S.;
- Tilly, H.;
- Houot, R.;
- Morschhauser, F.;
- Cartron, G.;
- Herbaux, C.
Publication type:
Article
A WIDE T‐CELL EXHAUSTION PATTERN IS FREQUENTIN THE TUMOR MICROENVIRONMENT OF RELAPSED/REFRACTORY B‐CELL LYMPHOMA PATIENTS AND COULD BE CIRCUMVENTED BY PDL1 BLOCKADE.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.10_2881
By:
- Laurent, C;
- Syrykh, C;
- Herbaux, C;
- Gat, E;
- Gravelle, P;
- Tarte, K;
- Cartron, G;
- Xerri, L
Publication type:
Article
BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 278, doi. 10.1002/hon.89_2630
By:
- Lemonnier, F.;
- Safar, V.;
- Ferchiou, A.;
- Cottereau, A.;
- Bachy, E.;
- Cartron, G.;
- Moles‐Moreau, M.;
- Delmer, A.;
- Bouabdallah, R.;
- Voillat, L.;
- Parrens, M.;
- Casasnovas, O.;
- Cacheux, V.;
- Réguy, C.;
- Tilly, H.;
- Meignan, M.;
- Gaulard, P.;
- Leval, L.;
- Delfau‐Larrue, M.;
- Haioun, C.
Publication type:
Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
By:
- Delfau‐Larue, M.H.;
- Boulland, M.L.;
- Feugier, P.;
- Maisonneuve, H.;
- Casasnovas, O.;
- Haioun, C.;
- Pica, G.M.;
- Lamy de la Chapelle, T.;
- Ysebaert, L.;
- Tilly, H.;
- Eisenmann, J.C.;
- Le Gouil, S.;
- Ribrag, V.;
- Jardel, H.;
- Glaisner, S.;
- Cartron, G.;
- Salles, G.;
- Xerri, L.;
- Fest, T.;
- Morschhauser, F.
Publication type:
Article
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 99, doi. 10.1002/hon.64_2629
By:
- Tournilhac, O.;
- Truemper, L.;
- Ziepert, M.;
- Bouabdallah, K.;
- Nickelsen, M.;
- Maury, S.;
- Reimer, P.;
- Jaccard, A.;
- Herr, W.;
- Wilhelm, M.;
- Cartron, G.;
- Wulf, G.;
- Sanhes, L.;
- Dreger, P.;
- Lamy, T.;
- Kroschinsky, F.;
- Lindemann, H.;
- Roussel, M.;
- Viardot, A.;
- Sibon, D.
Publication type:
Article
CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD.
Published in:
Hematological Oncology, 2019, v. 37, p. 370, doi. 10.1002/hon.38_2631
By:
- Mollaret, E.;
- Gomez, E.;
- Nadel, B.;
- Naiglin, L.;
- Anquetin, M.;
- Barau, C.;
- Baseggio, L.;
- Bret, C.;
- Brisou, G.;
- Brousset, P.;
- Camara‐Clayette, V.;
- Cartron, G.;
- Da Cunha, K.;
- Dartigues, P.;
- Dupuis, J.;
- Ghaleh, B.;
- Gravelle, P.;
- Houot, R.;
- Karmous‐Gadacha, O.;
- Laurent, C.
Publication type:
Article
SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 517, doi. 10.1002/hon.203_2631
By:
- Palomba, M.L.;
- Cartron, G.;
- Popplewell, L.;
- Ribrag, V.;
- Westin, J.;
- Chitra, S.;
- Huw, L.;
- Newberry, K.;
- Raval, A.;
- Xu, J.;
- Morschhauser, F.
Publication type:
Article
SAFETY AND EFFICACY OF ATEZOLIZUMAB, OBINUTUZUMAB AND VENETOCLAX COMBINATION FOR RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMAS: RESULTS FROM THE SAFETY‐RUN OF A LYSA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 332, doi. 10.1002/hon.144_2630
By:
- Herbaux, C.;
- Feugier, P.;
- Tilly, H.;
- Salles, G.;
- Gressin, R.;
- Le Gouill, S.;
- Morschhauser, F.;
- Cartron, G.
Publication type:
Article
REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM.
Published in:
Hematological Oncology, 2019, v. 37, p. 301, doi. 10.1002/hon.110_2630
By:
- Thieblemont, C.;
- Le Gouill, S.;
- Di Blasi, R.;
- Cartron, G.;
- Morschhauser, F.;
- Bachy, E.;
- Paillassa, J.;
- Bernard, S.;
- Tessoulin, B.;
- Gastine, T.;
- Fegueux, N.;
- Kanouni, T.;
- Manier, S.;
- Sesques, P.;
- Houot, R.;
- Haouin, C.;
- Tilly, H.;
- Salles, G.
Publication type:
Article
BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL.
Published in:
Hematological Oncology, 2019, v. 37, p. 278, doi. 10.1002/hon.89_2630
By:
- Lemonnier, F.;
- Safar, V.;
- Ferchiou, A.;
- Cottereau, A.;
- Bachy, E.;
- Cartron, G.;
- Moles‐Moreau, M.;
- Delmer, A.;
- Bouabdallah, R.;
- Voillat, L.;
- Parrens, M.;
- Casasnovas, O.;
- Cacheux, V.;
- Réguy, C.;
- Tilly, H.;
- Meignan, M.;
- Gaulard, P.;
- Leval, L.;
- Delfau‐Larrue, M.;
- Haioun, C.
Publication type:
Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
By:
- Delfau‐Larue, M.H.;
- Boulland, M.L.;
- Feugier, P.;
- Maisonneuve, H.;
- Casasnovas, O.;
- Haioun, C.;
- Pica, G.M.;
- Lamy de la Chapelle, T.;
- Ysebaert, L.;
- Tilly, H.;
- Eisenmann, J.C.;
- Le Gouil, S.;
- Ribrag, V.;
- Jardel, H.;
- Glaisner, S.;
- Cartron, G.;
- Salles, G.;
- Xerri, L.;
- Fest, T.;
- Morschhauser, F.
Publication type:
Article
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 99, doi. 10.1002/hon.64_2629
By:
- Tournilhac, O.;
- Truemper, L.;
- Ziepert, M.;
- Bouabdallah, K.;
- Nickelsen, M.;
- Maury, S.;
- Reimer, P.;
- Jaccard, A.;
- Herr, W.;
- Wilhelm, M.;
- Cartron, G.;
- Wulf, G.;
- Sanhes, L.;
- Dreger, P.;
- Lamy, T.;
- Kroschinsky, F.;
- Lindemann, H.;
- Roussel, M.;
- Viardot, A.;
- Sibon, D.
Publication type:
Article
CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD.
Published in:
Hematological Oncology, 2019, v. 37, p. 370, doi. 10.1002/hon.38_2631
By:
- Mollaret, E.;
- Gomez, E.;
- Nadel, B.;
- Naiglin, L.;
- Anquetin, M.;
- Barau, C.;
- Baseggio, L.;
- Bret, C.;
- Brisou, G.;
- Brousset, P.;
- Camara‐Clayette, V.;
- Cartron, G.;
- Da Cunha, K.;
- Dartigues, P.;
- Dupuis, J.;
- Ghaleh, B.;
- Gravelle, P.;
- Houot, R.;
- Karmous‐Gadacha, O.;
- Laurent, C.
Publication type:
Article
SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 517, doi. 10.1002/hon.203_2631
By:
- Palomba, M.L.;
- Cartron, G.;
- Popplewell, L.;
- Ribrag, V.;
- Westin, J.;
- Chitra, S.;
- Huw, L.;
- Newberry, K.;
- Raval, A.;
- Xu, J.;
- Morschhauser, F.
Publication type:
Article
SAFETY AND EFFICACY OF ATEZOLIZUMAB, OBINUTUZUMAB AND VENETOCLAX COMBINATION FOR RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMAS: RESULTS FROM THE SAFETY‐RUN OF A LYSA STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 332, doi. 10.1002/hon.144_2630
By:
- Herbaux, C.;
- Feugier, P.;
- Tilly, H.;
- Salles, G.;
- Gressin, R.;
- Le Gouill, S.;
- Morschhauser, F.;
- Cartron, G.
Publication type:
Article
REAL‐WORLD RESULTS ON CD19 CAR T‐CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE PROGRAM.
Published in:
Hematological Oncology, 2019, v. 37, p. 301, doi. 10.1002/hon.110_2630
By:
- Thieblemont, C.;
- Le Gouill, S.;
- Di Blasi, R.;
- Cartron, G.;
- Morschhauser, F.;
- Bachy, E.;
- Paillassa, J.;
- Bernard, S.;
- Tessoulin, B.;
- Gastine, T.;
- Fegueux, N.;
- Kanouni, T.;
- Manier, S.;
- Sesques, P.;
- Houot, R.;
- Haouin, C.;
- Tilly, H.;
- Salles, G.
Publication type:
Article
FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 141, doi. 10.1002/hon.2437_131
By:
- Gressin, R.;
- Daguindau, N.;
- Tempescul, A.;
- Moreau, A.;
- Carras, S.;
- Cartron, G.;
- Schmitt, A.;
- Houot, R.;
- Dartigeas, C.;
- Pignon, J.;
- Corm, S.;
- Bannos, A.;
- Mounier, C.;
- Dupuis, J.;
- Macro, M.;
- Fleury, J.;
- Jardin, F.;
- Karlin, L.;
- Damaj, G.;
- Feugier, P.
Publication type:
Article
PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA.
Published in:
Hematological Oncology, 2017, v. 35, p. 159, doi. 10.1002/hon.2438_14
By:
- Blakemore, S.J.;
- Daigle, S.R.;
- McDonald, A.A.;
- Morschhauser, F.;
- Ribrag, V.;
- Salles, G.;
- McKay, P.;
- Tilly, H.;
- Schmitt, A.;
- Le Gouill, S.;
- Fruchart, C.;
- Radford, J.;
- Zinzani, P.L.;
- Assouline, S.;
- Cartron, G.;
- Dickinson, M.;
- Morin, R.;
- Wu, H.;
- Sausen, M.;
- Clawson, A.
Publication type:
Article
THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA 'TRANSFORMED' BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE.
Published in:
Hematological Oncology, 2017, v. 35, p. 115, doi. 10.1002/hon.2437_104
By:
- Federico, M.;
- Caballero, D.;
- Marcheselli, L.;
- Tarantino, V.;
- Sarkozy, C.;
- Lopez Guillermo, A.;
- Wondergem, M.;
- Kimby, E.;
- Rusconi, C.;
- Zucca, E.;
- Montoto, S.;
- Silva, M.G.;
- Aurer, I.;
- Paszkiewicz ‐ Kozik, E.;
- Cartron, G.;
- Morschhauser, F.;
- Alcoceba, M.;
- Chamuleau, M.;
- Lockmer, S.;
- Minoia, C.
Publication type:
Article
A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2017, v. 35, p. 137, doi. 10.1002/hon.2437_126
By:
- Palomba, M.L.;
- Till, B.G.;
- Park, S.I.;
- Morschhauser, F.;
- Cartron, G.;
- Marks, R.;
- Penuel, E.;
- Chitra, S.;
- Kuhn, M.;
- Popplewell, L.
Publication type:
Article

Found: 56